10/15/2013

Mimetogen Pharmaceuticals is enrolling patients in a late-stage study of its MIM-D3 ophthalmic solution, an experimental treatment for dry eye syndrome. The trial will evaluate the drug against a placebo. About 400 patients will participate.

Related Summaries